Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges) of $1.98 per ...

AstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus ...

By Samuel OWUSU ADUOMI In today’s fast-evolving business landscape, Public Relations (PR) is no longer a peripheral function—it is a strategic necessity. Organisations across industries are realising ...

The strong performance outlook is particularly impressive given the looming generic competition for some ... potentially impacting stock performance in the short to medium term.

Nvidia shares are still down by about 9% since DeepSeek rattled the market, and the stock is currently 13% off its all-time ...

The homegrown large language model’s runaway popularity has opened the door to all manner of profit-making schemes, from paid ...

Garden centres are a fundamental part of British culture. I recently was party to an online discussion in which I learnt that ...

Akums Drugs reported a decline of 66 per cent year-on-year (Y-o-Y) to Rs 65.18 crore as compared to Rs 193.7 crore ...

Many market commentators will tell you the stock market has never been so dangerously overconcentrated in so few stocks.

Generic Eng Standalone December 2023 Net Sales at Rs 58.97 crore, down 5.09% Y-o-Y Mar 01 2024 01:54 PM Generic Eng Standalone September 2023 Net Sales at Rs 37.20 crore, down 30.48% Y-o-Y Dec 04 ...

South AFrican Army soldiers on border protection duties had it relatively quiet in January as far as putting the brakes on illegal immigration but had their hands full confiscating contraband and ...

Some metrics suggest that a market downturn could be around the corner. Regardless of when the next bear market begins, it's important to start preparing now. The more steps you take right now ...